Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Dyspnoea, FEV1/FVC ratio, Fatigue, Forced vital capacity, Musculoskeletal chest pain
Clinical narrative: ribs hurt from coughing; severe asthma attack; nonproductive cough; had to take a nap; joint pain; coughing uncontrollably/coughing spells/coughing through the night/coughing 24 hours a day/severe coughing/nonproductive cough; severe breathing difficulty lasting longer than a month requiring use of rescue inhaler every 4 hours/ shortness of breath; bones felt heavy; tiredness; This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (severe breathing difficulty lasting longer than a month requiring use of rescue inhaler every 4 hours/ shortness of breath), BONE DISORDER (bones felt heavy), MUSCULOSKELETAL CHEST PAIN (ribs hurt from coughing), ASTHMA (severe asthma attack) and COUGH (coughing uncontrollably/coughing spells/coughing through the night/coughing 24 hours a day/severe coughing/nonproductive cough) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 040A21A and 031M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Sinus infection and Cautery to nose (which were 90% blocked). Concurrent medical conditions included Allergy to antibiotic (Levaquin), Fragrance sensitivity (chemical sensitivity to fragrances especially citrus perfumes), Seasonal allergy and Asthma (no major incidents since 2015; used to experience asthma attacks about every 3 months) since 2005. Concomitant products included FLUTICASONE PROPIONATE (FLONASE [FLUTICASONE PROPIONATE]) for Allergy NOS, BECLOMETASONE DIPROPIONATE (QVAR) from an unknown date to 05-Apr-2021 for Asthma, UBIDECARENONE (COQ10 [UBIDECARENONE]), AMINOBENZOIC ACID, BIOTIN, CHOLINE BITARTRATE, FOLIC ACID, INOSITOL, LECITHIN, VITAMIN B NOS (B100), POTASSIUM IODIDE, RIBES NIGRUM SEED OIL (BLACK CURRANT OIL [RIBES NIGRUM SEED OIL]) and PLANTAGO PSYLLIUM (PSYLLIUM HUSK [PLANTAGO PSYLLIUM]) for an unknown indication.   On 24-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-Mar-2021 at 11:00 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 25-Mar-2021, the patient experienced BONE DISORDER (bones felt heavy) and FATIGUE (tiredness). On 26-Mar-2021, the patient experienced DYSPNOEA (severe breathing difficulty lasting longer than a month requiring use of rescue inhaler every 4 hours/ shortness of breath). 26-Mar-2021, the patient experienced COUGH (coughing uncontrollably/coughing spells/coughing through the night/coughing 24 hours a day/severe coughing/nonproductive cough). On an unknown date, the patient experienced MUSCULOSKELETAL CHEST PAIN (ribs hurt from coughing), ASTHMA (severe asthma attack), COUGH (nonproductive cough), SOMNOLENCE (had to take a nap) and ARTHRALGIA (joint pain). The patient was treated with SALBUTAMOL SULFATE (ALBUTEROL [SALBUTAMOL SULFATE]) ongoing since an unknown date at a dose of UNK UNK, q4h; PREDNISONE at a dose of 30 mg once a day; AZITHROMYCIN (Z-PAK) at an unspecified dose and frequency; DOXYCYCLINE on 15-Apr-2021 at an unspecified dose and frequency and FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE, VILANTEROL TRIFENATATE (TRELEGY) ongoing since an unknown date at an unspecified dose and frequency. At the time of the report, DYSPNOEA (severe breathing difficulty lasting longer than a month requiring use of rescue inhaler every 4 hours/ shortness of breath), ASTHMA (severe asthma attack) and COUGH (coughing uncontrollably/coughing spells/coughing through the night/coughing 24 hours a day/severe coughing/nonproductive cough) had not resolved and BONE DISORDER (bones felt heavy), MUSCULOSKELETAL CHEST PAIN (ribs hurt from coughing), COUGH (nonproductive cough), SOMNOLENCE (had to take a nap), ARTHRALGIA (joint pain) and FATIGUE (tiredness) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 08-Apr-2021, COVID-19: negative (Negative) nasal swab test. On 08-Apr-2021, X-ray: infiltrates (Inconclusive) Streaky bibasilar airspace disease left greater than right. The cardiac silhouette was mildly enlarged. There were streaky airspace disease at both lung bases left greater than right. There was no evidence of vascular congestion, pleural effusion or tracheal deviation.. On 22-Apr-2021, X-ray: improvement (Inconclusive) second X-ray;Improvement in aeration of the bibasilar infiltrates with residual infiltrative change remaining in the left lung base. On 06-May-2021, FEV1/FVC ratio: 75 (Inconclusive) FEV1 was 1.96 liters, which was 117% of predicted. On 06-May-2021, Forced vital capacity: 2.61 liter (Inconclusive) which was 111% of predicted.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The patient's lung volumes were normal with the total lung capacity being 114% of predicted and residual volume 107% of predicted. The patient had a mild reduction in diffusion with the Diffusing capacity for carbon monoxide (DLCO) being 62% of predicted. On April 8 patient had her X-rays at urgent care.    This case was linked to US-MODERNATX, INC.-MOD-2021-170679 (E2B Linked Report). This case was linked to MOD-2021-117024 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 25-May-2021: case is valid now, patient and event information added, test results, medical history and con meds added On 04-Jul-2021: NNI_Received; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-170679:First dose case for different patient, same reported